|Home | About | Journals | Submit | Contact Us | Français|
Poor homing of systemically infused cells to disease sites may limit the success of exogenous cell-based therapy. In this study, we screened 9,000 signal transduction modulators to identify hits that increase mesenchymal stromal cell (MSC) surface expression of homing ligands that bind to ICAM-1, such as CD11a. Pretreatment of MSCs with Ro-31-8425, an identified hit from this screen, increased MSC firm adhesion to an ICAM-1-coated substrate in-vitro, and enabled targeted delivery of systemically administered MSCs to inflamed sites in-vivo in a CD11a (and other ICAM-1-binding domains)-dependent manner. This resulted in a heightened anti-inflammatory response. This represents a new strategy for engineering cell homing to enhance therapeutic efficacy and validates CD11a/ICAM-1 as potential targets. Altogether, this multi-step screening process may significantly improve clinical outcomes of cell-based therapies.
While exogenous cell therapy is a promising approach for treating several tragic diseases (de Girolamo et al., 2013), a major challenge is that the majority of cell types exhibit poor homing to disease sites (Karp and Leng Teo, 2009). Herein, we report for the first time a multi-step process that includes a medium-throughput screen to detect small molecules that improve targeting of systemically infused mesenchymal stromal cells (MSCs) to sites of inflammation. MSCs are promising candidates for cell therapy given their pleotropic properties (Hoogduijn et al., 2010; Prockop and Oh, 2012). Specifically, MSCs can be readily isolated from bone marrow, fat and other adult tissues, thus avoiding ethical issues, and can be expanded under ex-vivo conditions to obtain a sufficient quantity for transplantation (Dominici et al., 2006). They are considered immune-evasive (Ankrum et al., 2014), and their multi-lineage differentiation potential as well as potent immunomodulatory properties prompted their exploration in over 420 clinical trials as potential treatment for many tragic diseases (clinicaltrials.gov, December 2014). While results from preclinical animal studies have been encouraging and hundreds of millions of allogeneic MSCs can be safely administered systemically to patients, clinical trials have produced mixed results and the translational potential of MSCs has not yet been realized (Ankrum and Karp, 2010; Francois and Galipeau, 2012). The majority of clinical trials involve systemic infusion of MSCs, yet MSCs exhibit poor homing to diseased or damaged tissues (Ankrum and Karp, 2010). Key ligands of the classical cell homing cascade that mediate dynamic cell interactions with activated endothelium are minimally expressed by MSCs or lost during in-vitro expansion (Rombouts and Ploemacher, 2003; Sarkar et al., 2011). Modifying MSCs with homing ligands via DNA transfection and different surface modifications improves their targeting to diseased sites (Enoki et al., 2010; Sackstein et al., 2008; Sarkar et al., 2011). However, such approaches could be challenging to scale-up in a cost-effective manner, and include safety concerns in the case of viral modifications. Manipulation of signaling pathways via small molecule pretreatment is a simple, cost-effective and scalable approach to improve control over cell fate. Furthermore, as small molecule pretreatment only transiently activates signal transduction pathways and because the small molecule is not directly delivered to patients, safety is another advantage. Although several high throughput screens of bioactive compounds have been performed to identify molecules that modulate cellular processes relevant to cell therapy, few have been translated into promising in-vivo preclinical results (Cutler et al., 2013). For instance, a zebrafish high-throughput screen yielded a stabilized prostaglandin that improves hematopoietic stem cell homeostasis and is currently being examined in a Phase-II clinical trial (Cutler et al., 2013). In this study, we describe a screening platform to identify small molecules that augment MSC therapeutic potential via increased adhesion to ICAM-1. Ro-31-8425, identified in this screen to upregulate CD11a expression, enhanced MSC firm adhesion to ICAM-1, promoted targeting of systemically infused MSCs to sites of inflammation and boosted their therapeutic impact.
In this study, we aimed to increase MSC surface expression of key homing ligands via small molecule pretreatment to improve homing of systemically administered MSCs to sites of inflammation (graphical abstract). Integrins, such as VCAM-1, were previously implicated in MSC homing (Teo et al., 2012), and engineering MSCs (via antibody (Ab) coating or viral DNA transfection) to over-express integrins can promote targeting of systemically infused MSCs to disease sites (Ko et al., 2010; Kumar and Ponnazhagan, 2007). We focused on surface expression of ligands that bind ICAM-1, such as CD11a, otherwise known as integrin alpha L (ITGAL). CD11a combines with integrin beta 2 (CD18) to create lymphocyte function-associated antigen-1 (LFA-1), which serves a central role in mediating leukocyte firm adhesion, an important step in the inflammatory leukocyte homing cascade (Luster et al., 2005).
For detection of CD11a on cell surface, we used a PE-CY5-conjugated anti-CD11a Ab. As shown in Fig.1a, CD11a is highly expressed on promyelocytic leukemia cells (HL-60, positive control), but not on the surface of culture-expanded MSCs. This anti-CD11a Ab was then used in a medium-throughput screening of 9,000 compounds, including a proprietary collection of 2,500 signaling pathway modulators, to identify candidate molecules that increase expression of CD11a on the MSC surface. Cells were pretreated with each small molecule (24h), followed by incubation with a PE-CY5-conjugated anti-CD11a Ab to detect its expression on the MSC surface (Fig.1b and Experimental procedures). Our screen identified 6 compounds that significantly increased the expression of CD11a on the MSC surface. The most potent molecule emerging from this screen was the kinase inhibitor Ro-31-8425 (CAS# 131848-97-0) (Fig.S1a), previously shown to have an inhibitory effect on PKC (Muid et al., 1991). As shown Fig.1c, Ro-31-8425 induced a dose-dependent increase in the percentage of CD11a-positive MSCs as quantified by mass cytometry (CyTOF, see Experimental Procedures). Evaluation of MSC viability demonstrated that Ro-31-8425 did not significantly compromise cell viability at concentrations of 0.25-4μM following a 24h pretreatment (Fig.S1b, Ro-31-8425 exhibited toxicity only at >4μM post 72h pretreatment of MSCs) and did not upregulate mRNA levels of CD18 (integrin β2, known to pair with CD11a to form LFA-1, Fig.S1c). Of note, Ro-31-8425 did not substantially alter the MSC secretome (Fig.S1d, out of 48 secreted factors tested via Ab-based multiplex assays, only 3 showed statistically significant changes in response to Ro-31-8425 pretreatment).As shown in Fig.1c, CyTOF analysis demonstrated that Ro-31-8425 treatment at 3μM triggered a significant increase in the percentage of MSCs exhibiting surface expression of CD11a compared to virtually no CD11a+ MSCs under control conditions. The percentage of CD11a+ MSCs in response to Ro-31-8425 (3μM for 24h) was stable for at least 4 days (Fig.S2a, similar pretreatment conditions were used for all subsequent experiments). As shown in Fig.1d, RT-PCR analysis revealed that Ro-31-8425 also significantly increased CD11a mRNA levels in MSCs, with peak levels observed 14h post incubation, indicating an impact of Ro-31-8425 pretreatment on MSC CD11a also at the transcriptional level. Importantly, Ro-31-8425 increased CD11a expression to a similar magnitude on MSCs from multiple donors (Fig.S2b). Establishing a donor-independent response is critical for successful clinical translation of exogenous cell therapy.
Considering the key role of CD11a in mediating leukocyte firm adhesion, we next assessed the effect of the identified CD11a-upregulating hits on MSC firm adhesion, which is part of the leukocyte adhesion cascade and is also governed by CD11a (Luster et al., 2005). CD11a is known to mediate leukocyte firm adhesion with endothelial cells via interaction with Intercellular Adhesion Molecules (ICAMs), and specifically ICAM-1 (Bhatia et al., 2003; Luster et al., 2005). Therefore, we tested firm adhesion of pretreated MSCs to ICAM-1, which is upregulated on the endothelial surface at sites of inflammation and is involved in leukocyte recruitment during inflammation (Kim et al., 2001; Luster et al., 2005; Wong and Dorovini-Zis, 1992). MSCs were incubated with each of the positive hits, and then subjected to a firm adhesion assay under physiologically relevant shear flow using a multiwell plate microfluidic system (Experimental Procedures) (Levy et al., 2013a). Pretreatment with Ro-31-8425, which up-regulated CD11a expression, induced a > 3-fold increase in MSC firm adhesion to an ICAM-1-coated substrate compared to control, vehicle-treated MSCs (Fig.2a(i) and 2a(ii)). As depicted in Fig.2a(iii), Ro-31-8425 pretreatment induced ICAM-1 firm adhesion of a new MSC sub-population comprising 68% of the entire population, out of which ~7% are CD11a+ (Fig.1c) and the rest (61%) express other active ICAM-1-binding domains/adhesion molecules. Ro-31-8425 also increased MSC firm adhesion to E-selectin-coated surface, further indicating that Ro-31-8425 induces upregulation/activation of additional adhesion molecules on the MSC surface (Fig.S3c). In contrast, the PKC inhibitor ruboxistaurin (Joy et al., 2005; Tang et al., 2008) that also belongs to the chemical family of bisindoles (Fig.S3a) but did not increase MSC CD11a expression in our screen (Fig.S3b), did not improve MSC firm adhesion to ICAM-1-coated substrates (Fig.2a).
To explore the possible involvement of CD11a in mediating pretreated MSC firm adhesion to an ICAM-1-coated surface, we performed Ab blocking experiments (Experimental Procedures). As shown in Fig.2b, incubating with CD11a blocking Ab significantly reduced Ro-31-8425-pretreated MSC firm adhesion to ICAM-1-coated surface (a reduction from ~90% of adhered cells to 50% following CD11a blocking). This data suggests that CD11a, which was upregulated in response to Ro-31-8425 pretreatment, is involved in mediating the increased MSC firm adhesion to ICAM-1. However, CD11a blocking did not fully abolish Ro-31-8425-pretreated MSC firm adhesion to control untreated MSC levels, further suggesting that other ICAM-1-binding ligands are also involved in mediating the increased firm adhesion of Ro-31-8425-treated MSCs to ICAM-1.
Compounds that significantly increased MSC firm adhesion to ICAM-1 in-vitro were then tested in-vivo for their ability to promote targeting of systemically administered MSCs to a distant site of inflammation. In our murine model, one ear pinna was injected with LPS to induce local inflammation, while the other received a saline injection (Experimental Procedures). This model was previously established to evaluate several MSC bioengineering strategies (Levy et al., 2013b; Sarkar et al., 2011), and has recently been modified to maximize sensitivity (Mortensen et al., 2013). Briefly, compound-treated and vehicle MSCs (stained with different membrane tracker dyes and mixed at 1:1 ratio) were systemically infused into mice and cell homing to the inflamed and control ears was imaged 24h later using intravital microscopy (Fig.3a and Experimental Procedures). Pretreatment with Ro-31-8425 significantly improved MSC homing to skin in the inflamed ear upon systemic administration, with an average of 45.2±8.6 cells/mm3 for vehicle-MSCs and 78.5±15.9 cells/mm3 for Ro-31-8425-MSCs (69.3±11.3% increase compared to vehicle-treated MSCs). This data demonstrates a strong relationship between surface expression of CD11a, ICAM-1 firm adhesion, and homing of systemically transplanted MSCs to sites of inflammation.
Furthermore, when CD11a was blocked on Ro-31-8425-pretreated MSCs prior to systemic infusion, their enhanced homing response to the site of inflammation was reversed, dropping from 70% to less than 10% increased homing vs. vehicle-treated MSCs (Fig.3b). These results further implicate CD11a and other ICAM-1 binding domains that mediate the enhanced homing response of systemically infused Ro-31-8425-pretreated MSCs to sites of inflammation. We then sought to assess the ability of Ro-31-8425-pretreated MSCs, which exhibited increased homing to the inflamed ear, to alleviate the severity of LPS-induced local inflammation. To evaluate ear inflammation, ear thickness and local levels of the pro-inflammatory cytokine TNF-α in mice ears were measured 24h post-administration of either vehicle or Ro-31-8425-pretreated MSCs (Experimental Procedures). As shown in Fig.3c, while mice treated with vehicle control MSCs exhibited a small reduction in ear thickness (6.3±5.2 μm reduction compared to no MSC treatment), MSCs pre-treated with Ro-31-8425 exhibited a greater than 3-fold effect in reducing ear swelling (20.0±5.3 μm reduction). LPS-induced inflammation resulted not only in ear swelling but also in a significant increase in local levels of the pro-inflammatory cytokine TNF-α in the inflamed ear compared to the saline-treated ear (4.5±1.3 fold TNF-α increase in the inflamed ear vs. control ear, Fig.3d). Consistent with the cell delivery and ear thickness data, the increased TNF-α levels in the inflamed ear were significantly reduced (~50%) by administration of Ro-31-8425-treated MSCs, whereas vehicle-treated MSCs did not impact TNF-α levels (Fig.3d). Taken together, these results show that systemic infusion of Ro-31-8425-pretreated MSCs, which displays CD11a and other ICAM-1 binding domains, increased homing to inflamed tissues and also results in improved anti-inflammatory therapeutic effect.
Our multi-step screening process identified small molecules that increased expression/activation of ICAM-1-binding ligands, such as CD11a, on the MSC surface, enhanced MSC firm adhesion to an ICAM-1-coated substrate and also promoted MSC homing to sites of inflammation following systemic administration, resulting in an improved anti-inflammatory response. Our findings are supported by a number of previous approaches that enhanced MSC therapeutic impact via improved homing to disease sites (Enoki et al., 2010; Ko et al., 2010). Recently, we have shown that mRNA-induced expression of SLeX/PSGL-1 (rolling ligands) resulted in a transient improvement of only 30% in MSC homing in the same local inflammation model and yielded a limited anti-inflammatory impact compared to untreated MSC (Levy et al., 2013b). In this system, targeted SLeX/PSGL-1 MSCs required simultaneous transfection with IL-10 mRNA to achieve a functional anti-inflammatory effect (Levy et al., 2013b). Ro-31-8425 pretreatment induced a ~70% increase in MSC delivery to an inflamed site (via increased firm adhesion), which was reversed when cells were blocked with a CD11a antibody, implicating CD11a and other ICAM-1 binding domains in mediating the increased homing response of MSCs to sites of inflammation. CD11a antibody blocking also significantly inhibited MSC firm adhesion to ICAM-1 in-vitro, though for a lesser extent (~50% inhibition), indicating that the antibody blocking in-vivo may have also blocked MSC interaction with additional ligands on the inflamed endothelium due to steric interference. Interestingly, the in-vitro ICAM-1 firm adhesion data, demonstrating a new ICAM-1-binding MSC sub-population (68% of the entire population) in response to Ro-31-8425 (comprised of 7% CD11a+ MSCs and an additional sub-population of 61% expressing other active ICAM-1-binding domains (Fig.2aiii)) correlates with the in-vivo data of ~70% increase in MSC homing to inflamed sites in response to Ro-31-8425 (Fig.3a). It is plausible that via modulation of key signaling pathways, Ro-31-8425 triggers firm adhesion to ICAM-1 (as well as to E-selectin) by inducing a slight upregulation (or conformational activation) of multiple adhesion molecules on the MSC surface, resulting in a broad and coordinated adhesion response. The improvement in MSC anti-inflammatory impact commensurate with the enhanced homing response demonstrated herein suggests that upregulation of firm adhesion ligands, and specifically utilization of the ICAM-1 axis, is an attractive target to improve the efficacy of cell-based therapies.
The most promising small molecule identified in our study was the kinase inhibitor, Ro-31-8425, previously demonstrated as a PKC inhibitor (Muid et al., 1991). Interestingly, PKC activation was shown to stimulate adhesion-mediated MSC retention in infarcted myocardium upon local administration by activation of focal adhesion kinase (Song et al., 2013). In our screen, we found that ruboxistaurin, a bis-indole that is chemically related to Ro-31-8425, as well as other PKC inhibitors, did not elicit CD11a expression on MSCs (Fig.S3b) and also did not increase MSC firm adhesion to ICAM-1 (Fig.2a). This implies that the Ro-31-8425-induced increase in RNA levels and surface expression of CD11a, MSC firm adhesion to ICAM-1 and systemic targeting of MSCs to an inflamed site were not PKC-dependent and potentially involves other kinases that may be targeted by Ro-31-8425, such as Rsk2, GSK-3β and CDK2 (Brehmer et al., 2004). This finding should stimulate further research to better understand involvement of signal transduction pathways in cell homing to sites of inflammation. Furthermore, correlating cell surface adhesion receptor expression to in-vitro and in-vivo adhesion, and to a therapeutic response, should enable further improvements for exogenous cell therapy, in which targeting cells to diseased or damaged tissues is highly important. The endothelial receptor expression on vessels in specific tissues is well characterized, providing zip codes that can be used to help identify new hits to enable delivery of cells to specific tissues. Hence, small molecule pretreatment can potentially serve as an effective methodology to target cells to virtually any tissue. Overall, the multi-step screening process described herein should provide an opportunity to significantly enhance the clinical efficacy of cell-based therapy.
MSCs were purchased from Lonza (donors used were 7F3915, 318006 and 351482) and expanded in MSCGM™ Mesenchymal Stem Cell Growth Medium (Lonza). Cells were kept at 37°C with 5% CO2 and media was changed every 3 days. Cells were passaged using 1% trypsin-EDTA solution. MSCs at passage 3-7 were used for all experiments. HL-60 cells were purchased from ATCC and seeded in Iscove's Modified Dulbecco's Medium-GlutaMax containing 20% FBS (Life Technologies).
MSCs were seeded on 384-well plates at 3,000 cells per well in MSCGM medium. Following an overnight incubation, cells were pretreated with a low (0.1 μM) and high (3 μM) concentration of the compounds for 24h (a total of 9,000 cpds were tested in 112 assay plates). Cells were washed and then incubated for 1h with PE-CY5-conjugated anti-CD11a monoclonal Ab (clone HI111, BD Biosciences). Expression of CD11a at the cell surface was detected using the Acumen Explorer®, a laser-scanning fluorescence microplate cytometer. Positive compounds were counter-screened for their auto-fluorescence by measuring the signal in the absence of Ab. Shown in Fig.1b is the global screening data. For further details, including signal/background ratio (green columns) and the Z’-factor (blue curve) calculations, see Supplemental Experimental Procedures.
Pre-confluent MSCs were incubated with Ro-31-8425 at the indicated concentrations for 24h or 72h and cell viability was assessed via an XTT assay according to manufacturer's instructions (ATCC).
MSCs (7F3915 or 318006) were seeded at 25,000 cells/well in a 12-well plate. 24h later, cells were treated with Ro-31-8425 (3μM) or 0.1% DMSO (control). Following 24h of treatment, secretomic samples were collected, centrifuged and frozen. MSC secretomes were assayed for the presence of cytokines, chemokines and growth factors using Bio-plex human 21-plex and 27-plex immunoassay kits (Bio-Rad), according to the manufacturer's instructions. The 27-plex and 21-plex panels consisted of the following analytes: IL-1α, IL-1β, IL-1Rα, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL12p40, IL12p70, IL-13, IL-15, IL-17, IL-18, CTACK, GROα, HGF, IFN-α2, LIF, MCP-1, MCP-3, MIF, MIG, β-NGF, SCF, SCGF-β, SDF-1α, TNF-α, TNF-β, TRAIL, Eotaxin, FGF-2, G-CSF, GM-CSF, IFN-γ, IP-10, MIP-1α, PDGF-bb, RANTES and VEGF. A standard range of 0.2-3,200 pg/mL was used. Samples and controls were run in triplicate, standards and blanks in duplicate (3 independent experiments were performed for each donor).
mRNA levels of CD11a in response to Ro-31-8425 pretreatment of MSCs were analyzed by qPCR. Specifically, MSCs were treated with Ro-31-8425 (3 μM) or vehicle control (0.1% DMSO) for 2h, 4h, 8h, 14h or 24 h. Cells were then trypsinized, washed with ice-cold PBS and pelleted (500g for 5 min at 4°C) at during the treatment and immediately stored at −80°C. RNA extraction was then performed as previously described (Tong et al., 2013), followed by a qPCR reaction using the following primers: for CD11α: 5’-CAGGCTATTTGGGTTACACCG-3’ (sense); 5’-CCATGTGCTGGTATCGAGGG-3’ (anti-sense); for CD18: 5’-TGCGTCCTCTCTCAGGAGTG-3’ (sense); 5’-GGTCCATGATGTCGTCAGCC-3’ (anti-sense). Also see Supplemental Experimental Procedures.
To further confirm the screening results, the surface expression of CD11a was also examined by Time of Flight Mass Cytometry (CyTOF2, DVS Sciences) (Newell et al., 2013). This approach, which uses metal-conjugated antibodies for detection of target proteins, was used to accurately assess CD11a expression levels on MSCs (using anti-human Nd142-labeled CD11a antibody, clone HI111) in response to Ro-31-8425, while minimizing any potential interference by the auto-fluorescent properties of this compound. MSCs were treated with Ro-31-8425 as indicated and sample preparation was performed per manufacturer's instructions. CyTOF data was analyzed with Cytobank on-line data analysis platform (https://www.cytobank.org/). Also see Supplemental Experimental Procedures.
Cell adhesion experiments were performed using Bioflux1000 (FluxionBio), allowing accurate control over shear flow (Levy et al., 2013a). A special 48-well plate was used, in which a microfluidic channel (350μm × 70μm) connects each pair of adjacent wells (termed inlet and outlet wells). The plate was placed under vacuum and the channels were coated from the inlet with recombinant human ICAM-1 (5 μg/mL) or E-selectin (5 μg/mL) Fc chimeras and incubated at 37°C for 1h. Prior to introducing the cells into the channel, a wash with PBS −/− from the outlet well was performed for 5min. Compound-pretreated MSCs were introduced into the channel, followed by an attachment period of 2 min (no flow applied during the attachment period). Attached cells were then subjected to increasing shear flow, ranging from 0.25 dynes/cm2 for up to 10 dynes/cm2. Images were acquired using the Montage software and cell adhesion to the ICAM-1-coated channels following subjection to shear flow was examined.
MSCs pretreated as indicated were detached, washed and incubated for 30 min with a mouse anti-human CD11a blocking Ab (clone: TS1/22) or a mouse IgG1 isotype control. Cells were then introduced into the microfluidic channel and subjected to a firm adhesion assay on ICAM-1-coated channels.
To track MSCs in-vivo, cells were stained with lipophilic membrane dyes with emission wavelengths in the red (DiI) or far red (DiD) (Invitrogen), with the dye pair selected based on previous work (Mortensen et al., 2013). MSCs (106 cells/mL) were incubated with 10μM DiI or 10μM DiD in PBS + 0.1% BSA for 20min at 37°C. MSCs were then washed twice in PBS and mixed in equal numbers for injection.
C57BL/6 mice (Charles River Laboratories) were anesthetized with ketamine/xylazine and their ears shaved 24 h prior to cell infusion. To induce an inflammatory response, 30 μg of E. coli lipopolysaccharide in 50 μL saline was injected into the pinna of the left ear, with 50 μL 0.9% saline injected into the right ear as a control. To evaluate the impact of Ro-31-8425 pretreatment on MSC homing to the inflamed ear, MSCs were incubated in cell culture media with 3 μM Ro-31-8425 (dissolved in 0.1% DMSO) or 0.1% DMSO vehicle alone as a control for 24 h before staining and in-vivo administration. Cells were stained prior to infusion as described above. For Ab blocking experiments, pretreated or control MSCs were washed and incubated for 30 min with mouse anti-human CD11a (clone TS1/22) or Mouse IgG1 isotype control, followed by two washing steps in PBS prior to staining with the Vybrant dyes. After staining, 4×104 cells of each condition were suspended in 150 μL PBS (pH 7.4) and injected by retro-orbital vein infusion into each mouse, so that each mouse received vehicle treated-MSCs of one color and Ro-31-8425 pretreated-MSCs of another. The stain color pair was switched between mice to correct for detection sensitivity. To highlight the vasculature, FITC-dextran (2×106 kDa) was injected retro-orbitally prior to imaging. Studies were in accordance with U.S. National Institutes of Health guidelines for care and use of animals under approval of the Institutional Animal Care and Use Committees of Massachusetts General Hospital and Harvard Medical School.
In-vivo homing of MSCs to the skin was imaged (24h post cell infusion) noninvasively in real time using a custom-built video-rate laser-scanning confocal microscope designed specifically for live animal imaging as previously described (Mortensen et al., 2013). Also see Supplemental Experimental Procedures.
To determine the impact of small molecule pretreatment on MSC therapeutic potential, ear swelling was measured. As a baseline, we measured ear thickness of all mice to be used using a caliper (Mitutoyo Inc.) and found no difference. Each measurement was taken 3 times with the average value recorded, and care taken to ensure minimal compression. Inflammation was then induced as described above. 24h later, mice (n=4-8 per group) were infused with no MSCs, MSCs (106/20 g body weight) pretreated for 24h with 0.1% DMSO, or MSCs (106/20 g body weight) pretreated for 24h with 3μM Ro-31-8425. 24h after cell infusion, ear thickness was measured using a caliper as before. To evaluate TNF-α secretion, LPS-induced inflammation and MSC administration were performed as described above with n = 4-6 mice for each condition. Mice were sacrificed 24h after cell administration and both ears were harvested. Ears were then ground in ice-cold extraction buffer (RIPA with 0.5% Tween-20) using a homogenizer, homogenates were centrifuged at 13,000xg for 10 min at 4°C, and the level of mouse TNF-α level in the supernatant samples was quantified using an anti-mouse TNF-α ELISA kit (Biolegend).
The authors wish to thank Sophie Fontaine and Céline Chansac from Sanofi for their technical support. This work was supported by a research grant from Sanofi-Aventis U.S. to JMK and CPL, and by National Institutes of Health grants HL095722 to JMK and P41 EB015903-02S1 to CPL.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
OL and LJM co-wrote the paper, designed experiments, performed experiments, analyzed and interpreted data. GB, ZT, CP, BB, JZ Designed experiments, performed experiments, analyzed and interpreted data. TS, EH, HS, JM and ZY performed experiments and analyzed data. MC, JR and JFD designed experiments and interpreted data. CPL and JMK co-wrote the paper, designed experiments and interpreted data.
GB, CP, BB, JZ, MC and JR are employed by Sanofi. JMK consults in the field of cell therapy for Stempeutics, Sanofi, and Mesoblast.